Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy.

scientific article published on 8 November 2013

Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3109/00365548.2013.844350
P698PubMed publication ID24206450
P5875ResearchGate publication ID258425627

P50authorVishesh PaulQ82787793
P2093author name stringYizhak Kupfer
Nisarg Changawala
Joost van Ginkel
Edward Chapnick
Sriharsha Rao
Ceres Tiu
Robbert Crusio
P2860cites workAssociation between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremiaQ45086694
Clinical and economic consequences of ventilator-associated pneumonia.Q45925029
Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.Q45974680
Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.Q46016195
Cluster of bloodstream infections caused by KPC-2 carbapenemase-producing Klebsiella pneumoniae in ManhattanQ46105767
Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) GroupQ21195082
A new method of classifying prognostic comorbidity in longitudinal studies: development and validationQ29547376
Prediction of creatinine clearance from serum creatinineQ29615603
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions ConferenceQ29618757
2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care SettingsQ29619731
"Swimming in resistance": Co-colonization with carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii or Pseudomonas aeruginosaQ33648238
Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentariumQ34429494
Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patientsQ35065863
Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimensQ35867414
"Silent" dissemination of Klebsiella pneumoniae isolates bearing K. pneumoniae carbapenemase in a long-term care facility for children and young adults in Northeast OhioQ36115511
Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?Q36335694
Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infectionsQ37263364
Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapyQ37656243
Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategiesQ37996299
Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York CityQ39687830
In Vitro Evaluation of Antibiotic Synergy for Polymyxin B-Resistant Carbapenemase-Producing Klebsiella pneumoniaeQ41827843
Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates?Q41963870
In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemasesQ42031262
Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.Q42262051
In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemasesQ42577530
Co-carriage rates of vancomycin-resistant Enterococcus and extended-spectrum beta-lactamase-producing bacteria among a cohort of intensive care unit patients: implications for an active surveillance programQ43841688
Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemasesQ44298896
A prospective study of outcomes, healthcare resource utilization, and costs associated with postoperative nosocomial infectionsQ44445854
Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteriaQ44728336
P433issue1
P921main subjectepidemiologyQ133805
carbapenem antibioticQ410897
P304page(s)1-8
P577publication date2013-11-08
P1433published inInfectious DiseasesQ7429961
P1476titleEpidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy
P478volume46